Viatris Yönetim

Yönetim kriter kontrolleri 2/4

Viatris CEO'su Scott Smith, Apr2023 tarihinde atandı, in görev süresi 1.58 yıldır. in toplam yıllık tazminatı $ 16.27M olup, şirket hissesi ve opsiyonları dahil olmak üzere 6.3% maaş ve 93.7% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.007% ine doğrudan sahiptir ve bu hisseler $ 1.13M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 1.3 yıl ve 4.4 yıldır.

Anahtar bilgiler

Scott Smith

İcra Kurulu Başkanı

US$16.3m

Toplam tazminat

CEO maaş yüzdesi	6.3%
CEO görev süresi	1.6yrs
CEO sahipliği	0.007%
Yönetim ortalama görev süresi	1.3yrs
Yönetim Kurulu ortalama görev süresi	4.4yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Scott Smith'un ücretlendirmesi Viatris'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	-US$883m
Jun 30 2024	n/a	n/a	-US$646m
Mar 31 2024	n/a	n/a	-US$56m
Dec 31 2023	US$16m	US$1m	US$55m

Tazminat ve Piyasa: Scott 'ın toplam tazminatı ($USD 16.27M ) US pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 12.67M ).

Tazminat ve Kazançlar: Scott şirketinin tazminatını şirket performansıyla karşılaştırmak için yeterli veri yok.

CEO

Scott Smith (62 yo)

1.6yrs

Görev süresi

US$16,271,094

Tazminat

Mr. Scott Andrew Smith is Director at Viatris Inc. since December 29, 2022 and serves as its Chief Executive Officer since April 1, 2023. He serves as President of Global Inflammation and Immunology at Cel...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Scott Smith	CEO & Director	1.6yrs	US$16.27m	0.0072% $ 1.1m
Brian Roman	Chief Legal Officer	4yrs	US$4.11m	0.0057% $ 896.7k
Theodora Mistras	Chief Financial Officer	less than a year	Veri yok	Veri yok
Paul Campbell	Chief Accounting Officer	9.5yrs	Veri yok	0.011% $ 1.7m
Ramkumar Rayapureddy	Chief Information Officer	less than a year	Veri yok	Veri yok
Andrew Enrietti	Chief People Officer	3.8yrs	Veri yok	Veri yok
Menassie Taddese	President of Emerging Markets	no data	Veri yok	Veri yok
Derek Glover	Chief Quality Officer	no data	Veri yok	Veri yok
Lara Ramsburg	Chief Corporate Affairs Officer	no data	Veri yok	Veri yok
Jeffrey Nau	President of Viatris Eye Care Division	no data	Veri yok	Veri yok
Philippe Martin	Chief R&D Officer	less than a year	Veri yok	Veri yok
Corinne Le Goff	Chief Commercial Officer	less than a year	Veri yok	Veri yok

1.3yrs

Ortalama Görev Süresi

54yo

Ortalama Yaş

Deneyimli Yönetim: VTRS 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1.3 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Scott Smith	CEO & Director	1.9yrs	US$16.27m	0.0072% $ 1.1m
JoEllen Dillon	Independent Non-Executive Director	4.8yrs	US$400.01k	0.0049% $ 778.1k
Wyllie Cornwell	Independent Director	4yrs	US$370.01k	0.0051% $ 812.9k
Elisha Finney	Independent Director	1.9yrs	US$370.01k	0.0016% $ 249.9k
James Kilts	Independent Director	4yrs	US$370.01k	0.0098% $ 1.6m
Harry Korman	Independent Non-Executive Director	6.4yrs	US$375.01k	0.0080% $ 1.3m
Melina Higgins	Independent Non-Executive Chairman	11.8yrs	US$454.38k	0.015% $ 2.3m
Robert Coury	Chairman Emeritus & Senior Strategic Advisor	less than a year	US$41.50m	0.23% $ 35.8m
Mark Parrish	Independent Vice Chairman & Lead Independent Director	15.2yrs	US$450.01k	0.010% $ 1.6m
Rajiv Malik	Director	4.8yrs	US$12.48m	0.042% $ 6.7m
Richard Mark	Independent Non-Executive Director	4.8yrs	US$420.01k	0.0061% $ 958.4k
Leo Groothuis	Independent Director	1.5yrs	US$313.54k	0.0019% $ 294.2k

4.4yrs

Ortalama Görev Süresi

63yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: VTRS 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.4 yıldır).

Viatris Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Viatris Inc., Annual General Meeting, Dec 06, 2024

Director recently sold US$2.3m worth of stock

Director recently sold US$3.5m worth of stock

Director notifies of intention to sell stock

Director recently sold US$3.6m worth of stock

Director notifies of intention to sell stock

Recent updates

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Bargain Priced Viatris Reports Strong Q3 Earnings Results

Second quarter dividend of US$0.12 announced

Viatris Inc. Declares Quarterly Dividend, Payable on December 13, 2024

Viatris Inc., Annual General Meeting, Dec 06, 2024

Viatris Ahead Of Q3 Earnings: No Longer A 'Screaming' Bargain, But Still A Buy

Viatris Inc. Announces Positive Top-Line Results from Phase 3 Study of Effexor® in Japanese Adults with Generalized Anxiety Disorder (GAD)

Viatris Launches (Pr) Viagra ODF in Canada

Viatris Inc. to Report Q3, 2024 Results on Nov 07, 2024

Director recently sold US$2.3m worth of stock

Director recently sold US$3.5m worth of stock

Viatris Inc. Presents Late Breaking Abstract on Cenerimod at the 26th Asia-Pacific League of Associations for Rheumatology Annual Congress

Director notifies of intention to sell stock

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

First quarter dividend of US$0.12 announced

Viatris Inc. Revises Earnings Guidance for the Fiscal Year 2024

Viatris Inc. Declares Quarterly Dividend, Payable on September 13, 2024

Cooper Consumer Health SAS completed the acquisition of Substantially All of the Over-the-Counter Business of Viatris Inc. (NasdaqGS:VTRS).

Director recently sold US$3.6m worth of stock

Director notifies of intention to sell stock

Viatris: Revenues, Debt, Valuation And Strategy Under The Microscope

Viatris Inc. to Report Q2, 2024 Results on Aug 08, 2024

IQuest Enterprises Private Limited acquired API operations of Viatris in India.

Viatris: Skeptics Proven Right Once Again

Chief Legal Officer recently sold US$928k worth of stock

First quarter dividend of US$0.12 announced

Viatris Inc. Announces Quarterly Dividend, Payable on June 14, 2024

First quarter 2024 earnings: EPS misses analyst expectations

Inflation Reduction Act: A Bullish Catalyst For Viatris Inc.

Viatris Inc. to Report Q1, 2024 Results on May 09, 2024

Viatris Inc. Announces Launch of First Bioequivalent Generic Version of Copaxone 20 mg/mL Once-Daily in Canada

Viatris Stock: Way Too Undervalued With $1 Billion Buyback Potential

Viatris Inc. Announces the Launch of RYZUMVI (Phentolamine Ophthalmic Solution) 0.75% in the United States

Viatris Stock Is Still Worth Buying

President of Developed Markets recently sold US$3.0m worth of stock

Insud Pharma S.L.U. acquired Women Healthcare business of Viatris Inc. (NasdaqGS:VTRS).

President & Executive Director exercised options and sold US$3.3m worth of stock

Up 25%, I Still Believe 4%-Yielding Viatris Is Up To 60% Undervalued

Fourth quarter dividend of US$0.12 announced

New minor risk - Profit margin trend

Full year 2023 earnings: EPS misses analyst expectations

Viatris Inc. Declares Quarterly Dividend, Payable on March 18, 2024

Viatris Inc. to Report Fiscal Year 2023 Results on Feb 28, 2024

From Euphoria To Reality: Viatris' Tale Of Market Whirlwind

Viatris Announces CFO Changes

Viatris Inc. Appoints Leo Groothuis to Serve on the Compliance and Risk Oversight Committee, Executive Committee and Governance and Sustainability Committee

Upcoming dividend of US$0.12 per share at 5.2% yield

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Viatris Inc. Declares Quarterly Dividend, Payable on December 15, 2023

Viatris Inc., Annual General Meeting, Dec 15, 2023

Now 21% undervalued after recent price drop

Viatris Inc. Announces That Its President, Rajiv Malik, Will Be Retiring as an Executive of the Company Effective April 1, 2024

Viatris Inc. to Report Q3, 2023 Results on Nov 07, 2023

Viatris Inc. and Ocuphire Pharma, Inc. Announce Fda Approval of Ryzumvl™? (Phentolamine Ophthalmic Solution) 0.75% Eye Drops for the Treatment of Pharmacologically-Induced Mydriasis Produced by Adrenergic Agonists (E.G., Tropicamide) Agents

Viatris Reportedly in Talks to Sell European OTC Assets to CVC

Viatris Inc. Announces U.S. FDA Tentative Approval of Paediatric Formulation of Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC), Once-Daily Treatment for Children Living with HIV

Upcoming dividend of US$0.12 per share at 4.3% yield

Consensus EPS estimates increase by 11%

Viatris Inc. Declares Quarterly Dividend, Payable on September 15, 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Viatris Inc. and Kindeva Drug Delivery L.P. Announces Launch of Breyna (Budesonide and Formoterol Fumarate Dihydrate) Inhalation Aerosol

Viatris Inc. to Report Q2, 2023 Results on Aug 07, 2023

Holzer & Holzer, LLC Announces A Class Action Lawsuit Has Been Filed Against Viatris Inc

Viatris Inc. Announces Board Changes

Johnson Fistel, LLP Files Class Action Lawsuit Against Viatris Inc

Upcoming dividend of US$0.12 per share at 5.1% yield

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Viatris Inc. Reaffirms Revenue Guidance for the Full-Year 2023

CEO & Executive Director exercised options and sold US$972k worth of stock